Horizontal Tabs

Treatment Modalities 
Facilities/Translational Research 
Phase 1 Capability
  • Acute Myeloid Leukaemia
  • First-in-Man studies
  • Multi-centre Phase 1 studies

Centre specific translational research interest

  • Mutation and gene array analysis
  • New agent sensitivity screening (e.g. anti-cancer agents, Ret targeting) 
  • Biomarkers (e.g. IHC biomarker assay development (endocrine-resistant breast cancers))
Other Facilities 
  • Wales CTU
  • Clinical Research Facility


Sample collection
  • Tissue Banking Activity: Wales Cancer Bank: AML Cell Bank
  • Centre contact responsible for sample collection: Cancer Bank (A Parry-Jones), AML (Dr Paul White).


ECMC funding provides infrastructure support for early phase and translational research.  From the ECMC Cardiff portfolio, the following trials have been carried out.

Trial activity between 2012-2015:


Trial by disease type between 2012-2015: